Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone.

The MCR and t1/2 of D-Trp6 LRH, a potent analog of LRH, were compared to those of exogenous LRH. Studies were performed on eight normal subjects during and after cessation of a constant infusion of D-Trp6 LRH and LRH. The D-Trp6 LRH and LRH were quantitated individually by sensitive and specific RIAs which did not cross-react with the other peptide infused or fragments of the degraded peptides. High performance liquid chromatography of plasma from a patient infused with D-Trp6 LRH alone yielded one peak, which coeluted with D-Trp6 LRH. The kinetics of peptide clearance were biphasic, with a rapid and a slow component of elimination. The t1/2 of the rapid component of D-Trp6 LRH clearance was 18.7 +/- 1.8 (SEM) min. This was significantly longer (P less than 0.001) than the t1/2 for the LRH of 7.8 +/- 1.1 min. The MCRs for D-Trp6 LRH and LRH were 503.4 +/- 196.4 and 1766.6 +/- 404.3 ml/min, respectively (P less than 0.01). The longer t1/2 of D-Trp6 LRH compared to that of LRH reflects the slower clearance, which is probably due to a decreased rate of degradation. These findings indicated that the enhanced bioactivity of D-Trp6 LRH is in part due to a decreased rate of degradation.

[1]  D. Crighton,et al.  Relative activity, plasma elimination and tissue degradation of synthetic luteinizing hormone releasing hormone and certain of its analogues. , 1979, The Journal of endocrinology.

[2]  K. Chikamori,et al.  Distribution volume, metabolic clearance and plasma half disappearance time of exogenous luteinizing hormone releasing hormone in normal women and women with obesity and anorexia nervosa. , 1981, Acta endocrinologica.

[3]  B. Little,et al.  The disappearance of 7-H-3-d-aldosterone in the plasma of normal subjects. , 1961, The Journal of clinical investigation.

[4]  A. Schally,et al.  Synthesis and biological properties of (D-Ala-6, des-Gly-NH2-10)-LH-RH ethylamide, a peptide with greatly enhanced LH- and FSH- releasing activity. , 1974, Biochemical and biophysical research communications.

[5]  T. Baram,et al.  Enzymic degradation of luteinizing hormone-releasing hormone (LH-RH) by hypothalamic tissue. , 1974, Biochemical and biophysical research communications.

[6]  G. Fasman,et al.  Antibodies to Bradykinin and Angiotensin: A Use of Carbodiimides in Immunology , 1964, Science.

[7]  C. McMartin,et al.  Peptide hormones and their analogues: distribution, clearance from the circulation, and inactivation in vivo. , 1978, Pharmacological reviews.

[8]  D. Leroith,et al.  Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure. , 1977, The Journal of clinical endocrinology and metabolism.

[9]  L. E. Clemens,et al.  Metabolism and effects of synthetic gonadotropin-releasing hormone (GnRH) in children and adults. , 1975, The Journal of clinical endocrinology and metabolism.

[10]  N. Ling,et al.  PHARMACOLOGY OF HYPOTHALAMIC REGULATORY PEPTIDES , 1976, Clinical endocrinology.

[11]  T. Wagner,et al.  GNRH interaction with anterior pituitary. I. Determination of the affinity and number of receptors for GNRH in ovine anterior pituitary. , 1979, Biology of reproduction.

[12]  G. Niswender,et al.  Quantitation of endogenous and exogenous gonadotropin releasing hormone by radioimmunoassay. , 1973, The Journal of clinical endocrinology and metabolism.

[13]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.